MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F25%3AN0000008" target="_blank" >RIV/00027162:_____/25:N0000008 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00140487 RIV/65269705:_____/25:00081135

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/hon.70036" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/hon.70036</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hon.70036" target="_blank" >10.1002/hon.70036</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia

Popis výsledku v původním jazyce

Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despitesignificant advances in treatment, some patients progress to more aggressive forms of multiple myeloma, including extra-medullary disease or plasma cell leukemia. Although the exact molecular mechanisms are not known, several studies haveconfirmed the involvement of small extracellular vesicle‐enriched microRNAs in multiple myeloma progression. Therefore, weperformed expression profiling of these molecules in bone marrow plasma of multiple myeloma, extramedullary disease, andplasma cell leukemia patients using small RNA sequencing to identify novel molecules involved in disease pathogenesis. Intotal, 42 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT‐qPCRconfirmed elevated levels of miR‐140‐3p, miR‐584‐5p, miR‐191‐5p, and miR‐143‐3p in multiple myeloma patients comparedto extramedullary disease and plasma cell leukemia patients. Subsequent statistical analysis revealed significant correlationsbetween patient clinical characteristics or flow cytometry parameters and microRNA expression. These results indicate thatdysregulation of microRNAs could contribute to multiple myeloma progression.

Název v anglickém jazyce

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia

Popis výsledku anglicky

Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despitesignificant advances in treatment, some patients progress to more aggressive forms of multiple myeloma, including extra-medullary disease or plasma cell leukemia. Although the exact molecular mechanisms are not known, several studies haveconfirmed the involvement of small extracellular vesicle‐enriched microRNAs in multiple myeloma progression. Therefore, weperformed expression profiling of these molecules in bone marrow plasma of multiple myeloma, extramedullary disease, andplasma cell leukemia patients using small RNA sequencing to identify novel molecules involved in disease pathogenesis. Intotal, 42 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT‐qPCRconfirmed elevated levels of miR‐140‐3p, miR‐584‐5p, miR‐191‐5p, and miR‐143‐3p in multiple myeloma patients comparedto extramedullary disease and plasma cell leukemia patients. Subsequent statistical analysis revealed significant correlationsbetween patient clinical characteristics or flow cytometry parameters and microRNA expression. These results indicate thatdysregulation of microRNAs could contribute to multiple myeloma progression.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hematological Oncology

ISSN

0278-0232

e-ISSN

1099-1069

Svazek periodika

43

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

47

Strana od-do

—

Kód UT WoS článku

001397146000001

EID výsledku v databázi Scopus

2-s2.0-85214787722